Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer

Laryngoscope

Volumn 120, Issue 2, 2010, Pages 236-242

  Watkins, John M ^a   Zauls, A Jason ^a   Wahlquist, Amy H ^b   Shirai, Keisuke ^b   Garrett Mayer, Elizabeth ^b   Gillespie, M Boyd ^a   Day, Terry A ^a   Sharma, Anand K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cisplatin; Combined modality therapy; Head and neck neoplasms; Paclitaxel; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; DATA BASE; DISEASE CONTROL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DYSPHAGIA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HOSPITALIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KAPLAN MEIER METHOD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARYNGITIS; PRESCRIPTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SKIN TOXICITY; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RADIATION INJURIES; SURVIVAL RATE;

EID: 76249101921     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20536     Document Type: Article

References (26)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-1900.
2. Browman GP, Hodson DI, Mackenzie RJ, et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579-589.
3. Adelstein DJ, Li Y, Adams GL, et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
4. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349: 2091-2098.
5. Forastiere AA, Weber RS, Pajak T, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 2006;24(suppl 18);284s.
6. Al-Sarraf M, Leblanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer. Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
7. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-2864.
8. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1997;19:567-575.
9. Jeremic B, Milicic B, Dagovic A, et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2004;22: 3540-3548.
10. Flood W, Lee DJ, Trotti A, et al. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin Radiat Oncol 1999; 17:2390-2395.
11. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
12. Huguenin P, Glanzmann C, Taussky D, et al. Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Strahlenther Onkol 1998;174:397-402.
13. Taylor SG, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994;12:385-395.
14. Pignon JP, le Maitre A, Bourhis J, et al. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Bio Phys 2007;69(2 suppl): S112-S114.
15. Flood W, Lee DJ, Trotti A, et al. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin Radiat Oncol 1999; 9:64-69.
16. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26:2457-2463.
17. Wang H, Ryu J, Gandara D, et al. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol 2007;2:153-157.
18. Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 2006;24:1904-1909.
19. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 2008;26:3582-3589.
20. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
21. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-854.
22. Bourhis J, Sire C, Lapeyre M, et al. Accelerated versus conventional radiotherapy with concomitant chemotherapy in locally advanced head and neck carcinomas: results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2008;72(suppl 1):S31-S32.
23. Katori H, Tsukuda M, Watai K. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin, and 5-flurouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Cancer Chemother Pharmacol 2007;60:399-406.
24. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
25. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-1078.
26. Langer CJ, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP), and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2008;26(suppl):6006.